MELA Sciences Reports Its First Quarter 2014 Business and Financial Results
Marketwire - 22 mins ago
MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, today announced results for its fiscal 2014 first quarter (Q1'14) ended March 31, 2014. MELA will host a conference call today at 4:30 pm EDT to review its results and recent progress.
MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma
Marketwire - Thu May 08, 7:37AM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced statistically significant preliminary results of a study that measured the impact of predictive probability information (probability of lesion being melanoma and melanoma/high-grade) on dermatologists' decisions to biopsy ambiguous pigmented skin lesions.
Melanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference Call Tuesday, May 13th at 4:30 pm ET
Marketwire - Wed May 07, 4:24PM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release its first quarter 2014 financial results and provide an update on its activities on Tuesday, May 13, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane, and the Company's CFO, Robert Cook, will host a conference call at 4:30pm ET that day to review the Company's progress and to answer questions.
MELA Sciences Secures Final Investigative Site and Enrolls 100+ Patients for Post-Approval Study for MelaFind(R) System Optical Melanoma Diagnostic Device
Business Wire - Wed Apr 30, 7:37AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind(R) system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced that it has concluded an agreement with the sixth and final investigative site participating in the Company's post-approval study (PAS) of the MelaFind(R) system for the diagnosis of melanoma. More than 100 patients have been enrolled in the study to date.
Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
Business Wire - Wed Apr 09, 7:23AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind(R) system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook as Chief Financial Officer, filling the position which had been vacant since December 31, 2013. Mr. Cook brings over 20 years of experience in senior finance and management leadership roles in the healthcare and pharmaceutical industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc. (NASDAQ OMX First North and OTCQX:IMNP), a developer of antibody therapeutics for cancer treatment, following its merger with EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX:EPCT).
MELA Sciences Announces 2013 Fourth Quarter and Year-End Financial Results
Business Wire - Mon Mar 17, 3:00PM CDT
MELA Sciences, Inc. (NASDAQ:MELA), (the "Company"
MELA Sciences elects Samuel E. Navarro to board
M2 - Mon Mar 17, 5:16AM CDT
Optical diagnostic company MELA Sciences (NasdaqCM:MELA) revealed on Friday the addition of Samuel E. Navarro to its board of directors, increasing its members to eight.
Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director
Business Wire - Fri Mar 14, 6:55AM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the appointment of veteran medical device investment banker Samuel E. Navarro to the Board of Directors. Mr. Navarro's appointment brings MELA's Board to eight members.
MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
Marketwire - Tue Mar 11, 9:35AM CDT
Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty Financial News Newsletter. It follows up two previous articles written four years ago.
Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
Business Wire - Thu Mar 06, 8:36AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
Business Wire - Mon Feb 24, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The extension gives the Company until August 18, 2014 to regain compliance.
MELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Wed Feb 05, 4:15PM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock. Net proceeds to the Company from this offering are approximately $11.5 million.
Kakamega Small-Scale Farmers Get Sh29m World Bank Boost
by Hilton Otenyo - All Africa Global Media - Tue Feb 04, 4:43AM CST
SMALL scale farmers in Kakamega county have received Sh29 million through a World Bank funded project to boost income and reduce poverty.
Melanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
Business Wire - Mon Feb 03, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that were provided in the Form 8-K.
CORRECTING and REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 1:03PM CST
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.).
Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 8:44AM CST
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the Company's convertible preferred stock, common stock warrants and common stock. The investors in the transaction were funds managed by Sabby Management, LLC, which comprise the Company's largest existing beneficial shareholder, and Broadfin Capital, LLC. In conjunction with the financing, MELA Sciences' directors have agreed to purchase $150,000 in restricted common stock priced at $0.74 per share, yesterday's closing bid price for MELA's common stock.
Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
Business Wire - Thu Jan 30, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind(R) workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks to increase physicians' knowledge of developments in medical and cosmetic dermatology.
Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan. 26-30
Business Wire - Mon Jan 27, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30 am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team will be available for one-on-one meetings that day.